HCA Faces Securities Probe After Guidance Cut, Analysts Slash Targets
HCA sits 17% above its 52-week low of $330.
Summary
A securities probe has been launched into HCA's Q2 disclosures following its July 14 guidance cut, adding legal risk to the operational headwinds. The company pre-announced Q2 revenue of ~$20.23B and EPS of $7.62, but slashed full-year EPS guidance to $28.70-$30.50, citing a $1.0-$1.2B insurance headwind. Shares fell about 7% on the initial news, and analysts are now cutting targets—RBC to $435 from $534, Barclays to $402 from $427. The probe and target cuts are new developments this week, escalating the negative sentiment. The Q2 earnings call on July 24 will be critical for management to address the probe and outlook.
At the time of this announcement, HCA was trading at $385.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $82.3B. The 52-week trading range was $330.00 to $556.52. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.